Literature DB >> 21630307

Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.

Ayalew Tefferi1, Louis Letendre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21630307     DOI： 10.1002/ajh.22051

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  24 in total

Review 1.  An update on cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman
Journal:  Trends Cardiovasc Med       Date:  2014-07-22       Impact factor: 6.677

Review 2.  Cancer as a Risk Factor for Cardiovascular Disease.

Authors:  Dana Elena Giza; Gloria Iliescu; Saamir Hassan; Konstantinos Marmagkiolis; Cezar Iliescu
Journal:  Curr Oncol Rep       Date:  2017-06       Impact factor: 5.075

Review 3.  Ischemic Heart Disease: Special Considerations in Cardio-Oncology.

Authors:  Dana Elena Giza; Fernando Boccalandro; Juan Lopez-Mattei; Gloria Iliescu; Kaveh Karimzad; Peter Kim; Cezar Iliescu
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-05

Review 4.  Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective.

Authors:  Dana Elena Giza; Kostas Marmagkiolis; Elie Mouhayar; Jean-Bernard Durand; Cezar Iliescu
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

5.  Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.

Authors:  Jorge E Cortes; H Jean Khoury; Hagop Kantarjian; Tim H Brümmendorf; Michael J Mauro; Ewa Matczak; Dmitri Pavlov; Jean M Aguiar; Kolette D Fly; Svetoslav Dimitrov; Eric Leip; Mark Shapiro; Jeff H Lipton; Jean-Bernard Durand; Carlo Gambacorti-Passerini
Journal:  Am J Hematol       Date:  2016-04-13       Impact factor: 10.047

Review 6.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

7.  Bilateral renal artery stenosis in a patient with chronic myeloid leukemia treated with nilotinib.

Authors:  Tilde Kristensen; Else Randers; Jesper Stentoft
Journal:  Leuk Res Rep       Date:  2012-11-10

8.  Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy.

Authors:  E Bondon-Guitton; S Combret; M C Pérault-Pochat; M Stève-Dumont; H Bagheri; F Huguet; F Despas; A Pathak; J L Montastruc
Journal:  Target Oncol       Date:  2016-08       Impact factor: 4.493

9.  Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.

Authors:  Delphine Rea; Tristan Mirault; Thomas Cluzeau; Jean-François Gautier; François Guilhot; Hervé Dombret; Emmanuel Messas
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

Review 10.  Vascular toxic effects of cancer therapies.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-26       Impact factor: 32.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.